270 related articles for article (PubMed ID: 8893876)
1. Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett W; Huang P; Searcy CE; Gandhi V
Semin Oncol; 1996 Oct; 23(5 Suppl 10):3-15. PubMed ID: 8893876
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
Heinemann V; Schulz L; Issels RD; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):11-8. PubMed ID: 7481839
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
6. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Mercier C; Evrard A; Ciccolini J
J Clin Oncol; 2007 Oct; 25(30):4855; author reply 4855-6. PubMed ID: 17947739
[No Abstract] [Full Text] [Related]
7. Preclinical characteristics of gemcitabine.
Plunkett W; Huang P; Gandhi V
Anticancer Drugs; 1995 Dec; 6 Suppl 6():7-13. PubMed ID: 8718419
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of gemcitabine in lung cancer: part I.
Bunn PA
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
[No Abstract] [Full Text] [Related]
9. Preclinical, pharmacologic, and phase I studies of gemcitabine.
Storniolo AM; Allerheiligen SR; Pearce HL
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-2-S7-7. PubMed ID: 9194473
[TBL] [Abstract][Full Text] [Related]
10. [Clinical pharmacology of nucleoside analogues].
Milano G; Chamorey AL; Thyss A
Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
[TBL] [Abstract][Full Text] [Related]
11. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
12. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
[TBL] [Abstract][Full Text] [Related]
13. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
[TBL] [Abstract][Full Text] [Related]
14. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
[TBL] [Abstract][Full Text] [Related]
15. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Gandhi V; Legha J; Chen F; Hertel LW; Plunkett W
Cancer Res; 1996 Oct; 56(19):4453-9. PubMed ID: 8813140
[TBL] [Abstract][Full Text] [Related]
16. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Cory AH; Hertel LW; Kroin JS; Cory JG
Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
18. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines.
van Moorsel CJ; Veerman G; Ruiz van Haperen VW; Bergman AM; Jensen PB; Sehested M; Peters GJ
Adv Exp Med Biol; 1998; 431():661-5. PubMed ID: 9598148
[No Abstract] [Full Text] [Related]
[Next] [New Search]
